Skip to main
GMED

Globus Medical (GMED) Stock Forecast & Price Target

Globus Medical (GMED) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 31%
Buy 46%
Hold 23%
Sell 0%
Strong Sell 0%

Bulls say

Globus Medical is expected to continue its growth trajectory driven by a strong financial profile and focus on key areas such as recurring revenue, cost-cutting, and international expansion. The company's recent earnings beat and raised guidance further solidify its positive outlook. Additionally, GMED's investments in spinal robotics technology and imaging systems position them well for future success in the medical device industry.

Bears say

Globus Medical is facing potential upside from faster spine market growth, higher sales in Enabling Technologies, and maintained margins; however, downside risks such as slower uptake of robotics and imaging and lower product traction may result in a slightly below market performance. Additionally, risks from competition, staffing issues, macro factors, and the possibility of the GMED/Nuvasive merger not meeting expectations, make the stock a risky bet for investors. With a 2027E EBITDA multiple of ~8x, slightly above the low 5-year NTM EV/EBITDA multiple (~7.5x), the projected price target is $75.

Globus Medical (GMED) has been analyzed by 13 analysts, with a consensus rating of Buy. 31% of analysts recommend a Strong Buy, 46% recommend Buy, 23% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Globus Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Globus Medical (GMED) Forecast

Analysts have given Globus Medical (GMED) a Buy based on their latest research and market trends.

According to 13 analysts, Globus Medical (GMED) has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $100, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $100, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Globus Medical (GMED)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.